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Abstract
Neurodegenerative diseases are a class of chronic and complex disorders featuring progressive loss of neurons in distinct brain areas. The
mechanisms responsible for the disease progression in neurodegeneration are not fully illustrated. In this observational study, we have
examined diverse biochemical parameters in the caudate and putamen of patients with Lewy body diseases (LBDs) and Alzheimer disease
(AD), shedding some light on the involvement of oxidative damage and neuroinflammation in advanced neurodegeneration. We performed
Spearman and Mantel-Cox analyses to investigate how oxidative stress and neuroinflammation exert comprehensive effects on disease
progression and survival. Disease progression in LBDs correlated positively with poly (ADP-Ribose) and triggering receptors expressed on
myeloid cell 2 levels in the striatum of LBD cohorts, indicating that potential parthanatos was a dominant feature of worsening disease
progression and might contribute to switching microglial inflammatory phenotypes. Disease progression in AD corresponds negatively with
8-oxo-7,8-dihydro-2′-deoxyguanosine (8-oxo-dG) and myeloperoxidase concentrations in the striatum, suggesting that possible mitochondria
dysfunction may be involved in the progression of AD via a mechanism of β-amyloid entering the mitochondria and subsequent free
radicals generation. Patients with lower striatal 8-oxo-dG and myeloperoxidase levels had a survival advantage in AD. The age of onset also
affected disease progression. Tissue requests for the postmortem biochemistry, genetics, and autoradiography studies were approved
by the Washington University Alzheimer’s Disease Research Center (ADRC) Biospecimens Committee (ethics approval reference number:
T1705, approval date: August 6, 2019). Recombinant DNA and Hazardous Research Materials were approved by the Washington University
Environmental Health & Safety Biological Safety Committee (approval code: 3739, approval date: February 25, 2020). Radioactive Material
Authorization was approved by the Washington University Environmental Health & Safety Radiation Safety Committee (approval code: 1056,
approval date: September 18, 2019).
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Introduction
Neurodegenerative diseases are disorders defined by
progressive impairment of motor and/or cognitive function.
Neurodegenerative diseases lead to severe and restlessly
functional impairments for millions of people annually,
affecting individuals’ life quality and happiness, burdening
their families and caregivers, as well as raising many healthrelated public concerns. There are no powerful therapies to

prevent or reduce disease progression. However, available
treatments can alleviate some symptoms, accompanied
by ineffective consequences over time and final disruptive
symptoms. One of the most significant challenges in
neurodegenerative disease therapeutics is the clarification of
clinically meaningful endpoints to measure progression. The
pathogenesis of different neurodegenerative diseases shares
specific characteristics, as featured with Alzheimer disease
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(AD), Parkinson’s disease (PD), amyotrophic lateral sclerosis
(ALS), and Huntington’s disease (Cho, 2010; Cummings, 2017;
Katsuno et al., 2018).
Increased levels of oxidative damages have been reported in
all three stages of AD – mild cognitive impairment (MCI), early
AD, and late-stage AD (Nunomura et al., 2001; Reed et al.,
2009a, b), supporting the hypothesis that oxidative damages
may be one of the common pathological mechanisms at
different AD stages. The decreases in the antioxidant enzyme
activity may promote enlarged productions of free radicals,
leading to increased oxidative damages in the nuclear
and mitochondrial DNA during the progression from mild
cognitive impairment to early AD/AD (Migliore et al., 2005;
Guidi et al., 2006; Wang et al., 2006). Studies are consistent
with the assumption that oxidative damage originates in
the mild cognitive impairment brain is an early AD event
and contributes to the disease progression (Stephan et al.,
2012). β-amyloid (Aβ) has been shown to enter mitochondria,
generate free radicals, and cause oxidative damage in
postmortem brain neurons from patients with AD and
transgenic animal AD models (Cardoso et al., 2001; McLellan
et al., 2003; Reddy, 2006). PD is the second most universal
neurodegenerative disease featuring the aggregation of
α-synuclein (α-syn) and the loss of dopamine neurons in the
substantia nigra. As the resident macrophages and the chief
immune defenders of the central nervous system (CNS),
microglia protect against the subsequent dangers following
the accumulation of α-syn via different activated phenotypes
(Sanchez-Guajardo et al., 2010). Microglia-mediated
neuroinflammation and α-syn related disruption of cellular
homeostasis promote each other; this positive feedback loop
drives a worsening progression of neurodegeneration (Fellner
et al., 2011; Schapansky et al., 2015). Pathologically, dying
or dead dopaminergic neurons in PD release neuromelanin
pigment, which could be one of the factors activating
microglia (Wilms et al., 2003). Neuromelanin particles are
phagocytized by microglia, inducing microglial activation,
superoxide production, nitric oxide (NO), hydrogen peroxide
(H 2O 2), and pro-inflammatory cytokines and chemokines
(Zhang et al., 2011). Neuroinflammation and oxidative stress
affect and potentiate each other, amplifying persistent and
progressive neurodegeneration in PD. PD dementia (PDD),
dementia with Lewy bodies (DLB), and PD have common
clinical and neuropathological features and have been
aggregated conceptually across the spectrum of Lewy body
diseases (LBDs) (Lippa et al., 2007).
Recently, considerable advances in genome-wide association
studies (GWASs) have classified genetic loci for Mendelian
(or familial) neurodegenerative diseases (Gandhi and Wood,
2010; Pihlstrøm et al., 2017). The dominant disorders are
mostly sporadic and late-onset diseases caused by a complex
of proteins misfolding and accumulating due to genetic
mutations and environmental factors. Distinct biochemical
entities in various brain areas have contributed to the
understanding of neurodegenerative disease pathogenesis.
The striatum contains two important sub-regions that
receive input from different cortical regions – the caudate
and putamen (Draganski et al., 2008). The caudate nucleus
is implicated in diverse performances, including procedural
learning and working memory (Seger and Cincotta, 2005;
Hannan et al., 2010). The dorsal posterior putamen receives
its principal input from the motor and sensorimotor cortices
and contributes extensively to the regulation of motor circuits
(Del Campo et al., 2016).
Our laboratory has devoted considerable effort to the
research of the striatum in patients with neurodegenerative
diseases. We have found that the interactions between
dopamine and oxidative damage play critical roles in
advanced neurodegeneration (Li et al., 2020a). Chronic
oxidative stress most likely leads to microglial phenotype

changes between dystrophy and senescence (Han et al.,
2019; Xu et al., 2019). Interestingly, we have observed that
oxidative damages, generated by misfolded tau proteins and
dopamine metabolism, give rise to microglial dysfunction,
which reversely reduces tau propagation (Li et al., 2020b).
The physiological crosstalk between disease progression
in neurodegenerative diseases and oxidative damage and
neuroinflammation is still a lingering question. In this study,
we analyzed diverse biochemical parameters, determined by
our previous research and the clinical presentations of study
patients, to provide a comprehensive attempt at addressing
the possible correlations between striatal oxidative damages,
inflammation, and neurodegenerative progression and
survival.

Materials and Methods
Ethics statement
Following local ethical committee protocols, patients
gave written consent (Additional file 1) before cognitive
impairment or responsible caregivers handed over approval
antemortem or postmortem consent (Washington University
Institutional Review Board, Washington University School of
Medicine). Tissue requests for the postmortem biochemistry,
genetics, and autoradiography studies were approved by the
Washington University Alzheimer’s Disease Research Center
(ADRC) Biospecimens Committee (ethics approval reference
number: T1705, approval date: August 6, 2019). Recombinant
DNA and Hazardous Research Materials were approved by
the Washington University Environmental Health & Safety
Biological Safety Committee (approval code: 3739, approval
date: February 25, 2020). Radioactive Material Authorization
was approved by the Washington University Environmental
Health & Safety Radiation Safety Committee (approval code:
1056, approval date: September 18, 2019) (Additional file 2).
The study involving human tissue samples was conducted in
accordance with the Declaration of Helsinki.
Subjects
Clinically and neuropathologically well-analyzed human brain
tissues were gained from the Knight ADRC and the Movement
Disorders Center brain bank at Washington University School
of Medicine. Initially, we collected tissues from a population
of 10 PD patients (7 men, 3 women) aged 69–87 years at
death (mean: 78 ± 2), 8 PDD patients (7 men, 1 woman) aged
66–87 years at death (mean: 77 ± 3), 10 DLB patients (5 men,
5 women) aged 69–89 years at death (mean: 81 ± 2), 27 AD
patients (13 men, 14 women) aged 62–94 years at death
(mean: 82 ± 2), and 10 age-matched congnitively control cases
(6 men, 4 women) aged 72–93 years at death (mean: 83 ± 2)
who passed away from non-neuronal causes. The arbitrary
clinical distinction between DLB and PDD was achieved using
the McKeith et al. criteria (Hughes et al., 1992; McKeith et al.,
2005). Dementia level was classified by the Clinical Dementia
Rating (CDR) scale (Emre et al., 2007). Participants with a CDR
≥ 1 were enrolled following their clinical evaluation using the
CDR criteria for diagnosing dementia in PD. AD pathological
changes were evaluated using Braak staging (Thal and
Braak, 2005). Braak stages of amyloid-beta deposition are as
follows: (A) the initial accumulates in the basal neocortex,
(B) accumulations that extend into the adjacent areas of the
neocortex, and (C) heavy accumulations throughout the entire
cortex. Stages of neurofibrillary pathology are classified by
their presentation in the transentorhinal (I–II), limbic (III–IV),
and neocortical (V and VI) regions. There were no significant
discrepancies in the average age and postmortem interval
time across groups. All AD cases featured neurofibrillary
tangles (NFTs) (V: 13 patients; VI: 14 patients) and significantly
differed from those of the age-matched control cases (Average
amyloid-beta: A; NFTs: II). Also, all LBDs showed NFTs. PD
stages were defined by the Hoehn and Yahr scale (Hoehn
and Yahr, 2001). Sustained response to levodopa (L-dopa)
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is the supportive and positive criteria for LBDs, which were
evaluated through L-dopa test (Abramsky et al., 1971). The
clinical information and pathological characteristics are
recapitulated in Table 1.
Tissue collection
Brain tissues were harvested at the time of autopsy;
subsequently, the right hemisphere was coronally sectioned
and snap-frozen using liquid nitrogen vapor. Then, tissue
blocks were preserved at –80°C. Frozen coronal sections (20
µm) were prepared for autoradiography study. The caudate
and putamen were carefully cut using a scalpel from adjacent
cryosections and tested for biochemistry.
Laboratory determinations of eight biochemical parameters
All tissue samples or tissue slices were prepared immediately
before the assays. Concentrations of 8-oxo-7,8-dihydro-2′deoxyguanosine (8-oxo-dG), 8-oxo-7,8-dihydroguanosine
(8-oxo-G), myeloperoxidase (MPO), and poly (ADP-Ribose)
(PAR) in the samples were determined to evaluate oxidative
damages developed in the striatum of patients and agematched controls. Levels of triggering receptors expressed
on myeloid cell 2 (TREM2) in the striatum were analyzed
to understand the possible microglial phenotype changes
promoted by oxidative damages. Densities of translocator
protein (TSPO) and tau fibrils were quantified to estimate
the correlations between microglia dystrophy and tauopathy.
Additionally, dopamine levels in the caudate and putamen
were quantitatively measured. The detailed experimental
procedures for biochemistry and quantitative autoradiography
assays can be found in our previous reports (Li et al., 2020a, b).
Methods are briefly described below. All data are summarized
in Table 2.
8-oxo-dG and 8-oxo-G quantification
Total DNA and RNA in the caudate and putamen of study
brains were extracted separately using the Qiagen QIAamp
DNA Mini Kit (Qiagen, Valencia, CA, USA; Cat# 51304) and
the Qiagen RNeasy Plus Micro Kit (Qiagen; Cat# 74034). The
concentrations of 8-oxo-dG and 8-oxo-G were determined
separately using the OxiSelect oxidative DNA damage ELISA

(Cell Biolabs, Inc., San Diego, CA, USA; Cat# STA-320) and the
OxiSelect oxidative RNA damage ELISA kits (Cell Biolabs, Inc.,
Cat# STA-325-5).
MPO, PAR, and TREM2 quantification
B ra i n s a m p l e s we re h o m o ge n i ze d i n co m m e rc i a l l y
available lysis buffer (for MPO and TREM2, Fisher Scientific,
895347, Pittsburgh, PA, USA) or RIPA buffer (for PAR), the
supernatant was collected to determine the expression of
MPO, PAR, and TREM2 in the caudate and putamen using
the Myeloperoxidase Human ELISA kit (Abcam, ab119605,
Cambridge, MA, USA), PAR ELISA kit (Cell Biolabs, Inc., XDN –
5114, San Diego, CA, USA), and theTREM2 Human ELISA kit
(Biomatik, EKU07882, Wilmington, DL, USA), respectively.
Dopamine quantification
Brain samples were homogenized with PBS (Fisher Scientific;
Cat# 50-983-207), and the supernatant was collected for
quantification of dopamine levels in the caudate and putamen
using the dopamine ELISA kit (BioVision, Inc., Milpitas, CA,
USA, Cat# K4219).
TSPO and tau fibril quantification
The densities of TSPO and tau fibril in the caudate
and putamen from study brains were quantified using
autoradiography, [ 3H]PBR28 (80 Ci/mmol, CAS Number:
253307-72-1) and [3H]MK6240 (21.5 Ci/mmol, CAS Number:
1841078-87-2) were chosen as radioligands, respectively. The
TSPO gene was also genotyped to screen and exclude the lowaffinity binders for [3H]PBR28 autoradiography binding data
analysis.
Statistical analysis
Spearman’s correlation coefficient (rs) was calculated to assess
the strength of the correlation between continuous variables.
In this study, we estimated the correlations between patients’
clinical presentations: age at the onset of disease, disease
progression, Braak NFT stage, Braak Aβ stage, PD stage, and
8 biochemical parameters expressed in the caudate and
putamen samples from patients with neurodegenerative
diseases. Disease progression was calculated from the age

Table 1 ｜ Demographic characteristics of the study subjects

N
Male/female (n)
Age (yr)
PMI (h)
Brain weight (g)
Age of onset (yr)
Progression (yr)
Braak NFT stage

Control

PD

PDD

DLB

AD

P

10
6/4
83±2
18.8±5
1326±60

10
7/3
78±2
16.0±3.2
1299±40
65±3
14±1
Stage I: 5
Stage II: 2
Stage III: 3

8
7/1
77±3
10.8±1.6
1346±41
60±3
16±3
Stage I: 3
Stage II: 2
Stage III: 3

10
5/5
81±2
18.0±3.7
1273±38
66±4
14±3
Stage I: 7
Stage II: 2
Stage V: 1

27
13/14
82±2
10.6±1.0
1127±47
71±2
10±1
Stage V: 13
Stage VI: 14

NA
NA
NA
NA
NA
NA
*

Normal: 3
Stage A: 1
Stage B: 2
Stage C: 5
Stage 2: 2
Stage 2.5: 1
Stage 3: 4
Stage 4: 2
Yes: 9
Modest: 1

Normal: 1
Stage A: 2
Stage B: 1
Stage C: 4
Stage 2: 2
Stage 3: 3
Stage 4: 2
Stage 5: 1
Yes: 6
Modest: 2

Normal: 1
Stage A: 1
Stage B: 2
Stage C: 6
Stage 2.5: 2
Stage 3: 3
Stage 4: 2
Stage 5: 2
Yes: 9
Modest: 1

All stage C

NA

All normal

NA

Braak Aβ stage

Stage 0: 1
Stage I: 2
Stage II: 4
Stage III: 3
All normal

PD stage

All normal

L-Dopa response

Data are disclosed as the mean ± SEM. Braak Aβ stage: Braak amyloid-beta plaque stage; Braak NFT stage: Braak neurofibrillary tangle stage; PMI: Postmortem
Interval; PD stage: Parkinson disease stage. *P < 0.05, vs. control.
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Table 2 ｜ Biochemical parameters of study participants

Control CA
PU
PD
CA
PU
PDD
CA
PU
DLB
CA
PU
AD
CA
PU

8-oxo-dG
8-oxo-G
DA
(pg/µg total DNA) (pg/µg total RNA) (ng/g wet wt)

MPO (pM/g)

PAR (pM/g)

TREM2 (ng/g) TSPO (fmol/mg) Tau (fmol/mg)

20.7±2.58
16.6±1.93
11.2±1.46#
16.6±1.78
15.6±1.07
18.1±1.23
16.2±1.23
14.8±1.83
24.2±2.94
13.9±0.73

5569±1536
3245±732
4654±1871
4824±2552
4109±430
2802±373
2846±456
2582±432
3754±434
4316±728

5.11±1.97
3.45±1.25
2.52±1.03#
3.06±0.53
2.80±0.95#
2.34±0.64
1.53±0.20#
2.63±0.37
10.1±1.97
2.17±0.24

160±35.5
322±68.0
217±37.7
174±21.0
316±60.4
219±34.9
239±32.5
220±30.0
225±29.2
344±50.0

33.1±4.31
48.4±6.11
21.1±3.34
21.1±3.64**
31.9±5.68**
19.2±2.82
23.9±2.92
15.8±2.04****
27.9±2.76
40.4±3.12#

12.3±6.99
17.2± 5.08
8.3±2.66
7.5±4.73
9.8±3.38
6.4±2.75
19.0±10.3
15.1±7.00
24.3±4.86
21.1±3.00

732±140
648±143
178±24.6####
211±37.7###
270±40.1##
276±27.6##
225±49.9###
202±41.2###
1003±132
825±106

458±82.6
489±91.5
120±20.4####
121±24.4**
129±13.8####
134±16.4**
182±50.0####
213±51.2*
752±73.0
716±41.8*###

Data are disclosed as the mean ± SEM. 8-oxo-dG: 8-oxo-7,8-dihydro-2'-deoxyguanosine; 8-oxo-G: 8-oxo-7,8-dihydroguanosine; AD: Alzheimer disease; CA:
Caudate; DA: Dopamine; DLB: Dementia with Lewy body; LBDs: Lewy body diseases including PD, PDD, and DLB; MPO: myeloperoxidase; PAR: poly (ADP-Ribose);
PD: Parkinson disease; PDD: Parkinson disease dementia; PU: Putamen; TREM2: Triggering receptors expressed on myeloid cell 2; TSPO: Translocator protein.
*P < 0.05, **P < 0.01, ****P < 0.0001, vs. control; #P < 0.05, ##P < 0.01, ###P < 0.001, ####P < 0.0001, vs. LBDs (PD, PDD, and DLB).

of the onset to the age of death and expressed in years. We
used a log-rank (Mantel-Cox) test to estimate the relationships
between patient survival and the 8 biochemical parameters.
Mantel-Cox curves for the patient’s survival were constructed
according to high concentrations of the biochemical
parameter (above the mean value) and low concentrations of
the biochemical parameter (below the mean value). Statistical
analyses were achieved using GraphPad Prism 6.0 (GraphPad
Software Inc., San Diego, CA, USA; RRID: SCR_002798) for
Windows and IBM SPSS Statistics version 23 (IBM, Armonk,
NY, USA; RRID: SCR_002865). P < 0.05 was considered
statistically significant. No sample size calculations, blinding,
or randomizations were performed during the statistical
analyses.

Results
Demographic characteristics and biochemical parameters of
study subjects
In this study, 65 participants, aged between 62 and 94, met
the clinical diagnostic criteria: 10 PD subjects, 8 PDD subjects,
10 DLB subjects, 27 AD subjects, and 10 healthy control
subjects. Demographic characteristics of the disease and
age-matched control groups are presented in Table 1. There
were no significant differences in postmortem interval, age
at death, brain weight, age at onset, and disease progression,
suggesting that our results were not affected by these factors.
Braak neurofibrillary tangle stage (NFT) stages observed in the
AD group significantly differed from controls.
Moreover, levels of nucleic acid oxidative species and
dopamine, expressions of MPO, PAR, and TREM2, as well as
densities of TSPO and tau fibrils in the caudate and putamen
of the patients with neurodegenerative diseases and controls
were identical (Table 2).
Correlations of biochemical parameters and disease
progression in patients with neurodegenerative diseases
In the Spearman correlation analyses, PDD progression
positively depended on the concentration of PAR in the
caudate (rs = 0.786, P = 0.036; Figure 1A). We observed a
positive correlation between the TREM2 levels in the putamen
of PDD patients and disease progression (r s = 0.786, P =
0.036; Figure 1B). Then we examined whether the microglial
expression could be related to PDD disease progression.
It appears that there was a negative correlation between
TSPO levels in the putamen of the PDD group and disease
progression (rs = –0.857, P = 0.014; Figure 1C). We further
examined the LBD cohorts, and Spearman analyses revealed
positive correlations between PAR concentration in the
caudate of LBD brains and disease progression (rs = 0.539,

P = 0.010; Figure 1D), as well as TREM2 expression in the
putamen of LBD brains and disease progression (rs = 0.501, P =
0.013; Figure 1E). Interestingly, we found significant negative
correlations between 8-oxo-dG concentration in the putamen
of AD brains and disease progression (rs = –0.453, P = 0.020;
Figure 1F), as well as MPO levels in the caudate of AD brains
and disease progression (rs = –0.594, P = 0.003; Figure 1G).
Correlations between the age of the onset and disease
progression in patients with neurodegenerative diseases
T h o u g h t - p r o v o k i n g l y, w e f o u n d t h a t t h e a g e o f
onset associated with disease progression in all the
neurodegenerative diseases studied, as shown in Figure 2.
Spearman analyses uncovered negative correlations between
the age of onset and disease progression in PD, PDD, DLB,
and AD cohorts (Figure 2A–D). These results supported the
hypothesis that the older the patients were, the more severe
their clinical and neurophysiologic features, and that onset
age mainly altered the rate of progression (Kempster et al.,
2010; Pagano et al., 2016).
Correlations between PD stage and biochemical parameters
in patients with Lewy body diseases
LBD patients were stratified into different PD stages according
to the Hoehn and Yahr scale (Hoehn and Yahr, 2001).
We investigated the relationships between biochemical
parameters in the striatum and PD stages in LBD groups. A
significant negative correlation was observed between PD
stage and PAR concentration in the putamen of LBD brains
(rs = –0.462, P = 0.023; Figure 3A). Additionally, a significant
positive relationship was found between PD stage and TREM2
concentration in the putamen of LBD cohorts (rs = 0.421, P =
0.036; Figure 3B), which was in agreement with the positive
correlation between disease progression and TREM2 levels in
the putamen of LBD cases.
Impact of biochemical parameters in the striatum on the
survival of patients with AD
In the AD cohort, Mantel-Cox analyses revealed that patients
with a lower 8-oxo-dG concentration in the putamen had a
significant survival advantage over those with higher 8-oxo-dG
levels (P = 0.0195; Figure 4A), indicating that DNA oxidative
damage in the putamen played a critical role in patient
survival. Besides, there was a significant difference in survival
between AD cases with a higher MPO concentration in the
caudate and those with lower MPO concentration in the same
brain area (P = 0.0003; Figure 4B), suggesting MPO level in
the caudate is a potential positive risk factor for survival in AD
patients.
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Figure 1 ｜ The correlations of biochemical parameters in the caudate and putamen of patients with diseases and disease progression.
(A) PAR concentration in the caudate of PDD vs. disease progression. (B) TREM2 concertation in the putamen of PDD vs. disease progression. (C) TSPO density
in the putamen of PDD vs. disease progression. (D) PAR concentration in the caudate of LBDs vs. disease progression. (E) TREM2 concentration in the putamen
of LBDs vs. disease progression. (F) 8-oxo-dG level in the putamen of AD vs. disease progression. (G) MPO concentration in the caudate of AD vs. disease
progression. *P < 0.05, **P < 0.01. Sample size: PD, n = 10; PDD, n = 8; DLB, n = 10; AD, n = 27. 8-oxo-dG: 8-Oxo-7,8-dihydro-2′-deoxyguanosine; AD: Alzheimer
disease; DLB: dementia with Lewy bodies; LBDs: Lewy body diseases; MPO: myeloperoxidase; PD: Parkinson disease; PDD: PD dementia; PAR: poly (ADP-ribose);
rs: Spearman’s rank correlation coefficient; TREM2: triggering receptors expressed on myeloid cell 2; TSPO: translocator protein.
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Discussion
Neurodegenerative diseases are disorders featured by
progressive dysfunction of the motor and/or cognition.
Pathogenically, these diseases share common characteristics
– a vicious pathogenic cycle, including the accumulation of
insoluble proteins, disturbance of the redox homeostasis,
activation of glial cells, and death/loss of neurons.

Disease progression in Lewy body diseases
LBDs are a family of neurodegenerative disorders identified by
the presence of Lewy bodies, α-synuclein-positive inclusions
in the brain. LBDs mainly consist of PD, DLB, and PDD. DLB
is diagnosed as dementia that develops before or within 1
year of PD, and PDD is dementia manifesting in the context
of confirmed PD (McKeith et al., 2005; Emre et al., 2007).
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However, numerous metabolic and functional deficiencies
developed in the early stage of PD brains are promoted by
oxidative stress and mitochondrial abnormalities rather than
Lewy pathology (Ferrer, 2009).
We found significant positive correlations between disease
progression and PAR concentrations in the caudate of PDD
cases and LBD cohorts. Coincidently, PAR-dependent cell death
has been described to be prevalent in slowly progressing
dopaminergic neurodegeneration in PD mouse models (Lee et
al., 2013). Parthanatos – one form of cell death – was named
from the integration of “PAR” and “Thanatos”, Thanatos being
the god of death in Greek mythology (Fatokun et al., 2014).
Parthanatos can be generated by the accumulation of PAR
accompanied by the overactivation of PAR polymerase-1.
Excesses of PAR stimulates the mitochondrial release
of apoptosis-inducing factor (AIF), which, together with
macrophage migration inhibitory factor, enters the nucleus
and cleaves genomic DNA into large fragments (Park et al.,
2020). Aminoacyl-tRNA synthetase complex interacting
multifunctional protein-2 has been reported to be critically
involved in the dopaminergic cell death mediated by
parthanatos, indicating that PAR polymerase-1 inhibition
may practically slow the progression of Parkinson disease
(Lee et al., 2013). On the other hand, overactivation of PAR
polymerase-1 plays a crucial role in causing deterioration
of the blood-brain barrier, whose defense slows down PD
progression (Wu et al., 2014).
Impressively, in contrast to the caudate results, we found a
significant negative correlation between the PD stage and PAR
concentration in the putamen of LBD brains. PD stages are
defined by the Hoehn and Yahr Scale (Hoehn and Yahr, 2001).
Patients’ motor symptoms and secondary physical features get
worse as the disease progresses, as well as the advanced PD
stages, which can be proved further by the significant positive
correlation between PD stage and disease progression in
the LBD patients (Additional Figure 1; rs = 0.479, P = 0.015).
These results might indicate asymmetric biochemical and
pathological changes in the caudate and putamen of patients
with LBDs. The putamen of PD patients has been defined with
more deficiency in dopamine storage capacity, decreased
dopaminergic projections from the substantia nigra, increased
dopamine D2 receptor, and loss/or lower benzodiazepine
receptor and muscarinic receptor when compared with the
caudate of PD and AD cases (Griffiths et al., 1994; Rinne et al.,
1995; Otsuka et al., 1996; Kumakura et al., 2006). We firstly
reported the PAR concentrations in the caudate and putamen
of patients with neurodegenerative diseases. However, by
virtue of the small sample size for these groups, asymmetric
alterations in the PAR levels of the caudate and putamen still
need to be more robustly elucidated in further studies.
It was remarkable to find significant positive correlations
between disease progression/PD stage and TREM2 expressions
in the putamen of PDD cases and the LBD cohorts. TREM2
is expressed entirely by microglia within the central nervous
system, acting as a primary immune checkpoint that modulates
the microglial homeostatic pathway (Jay et al., 2017). TREM2
upregulation in the late-stage of AD progression was reported
in postmortem brains (Perez et al., 2017). Emerging evidence
shows that microglia can polarize into classic inflammatory M1
and immunosuppressive M2 phenotypes. TREM2 is beneficial
for switching between the M1 and M2 microglial phenotypes
and is especially essential for M2 microglia polarization (Belloli
et al., 2017). In a previous report, diverse stages of diseaseassociated-microglia were modulated independently and/or
dependently by TREM2. This finding, along with our results,
suggests high microglial heterogeneity in individual patients
during the disease progression or stages (Masuda et al., 2020).
Upregulation of TREM2 levels in the late disease progression
seems to be a compensatory attempt of TREM2 to alleviate
the microglial over-activation or ameliorate dystrophic,

or senescent, microglial types (Zhang et al., 2018). This
hypothesis was supported further by the significant negative
correlation between disease progression and TSPO density
in the putamen of PDD patients – a marker of brain microglia
activation.
Disease progression and survival in AD
Information obtained from studies of familial AD models
might also be applicable to sporadic AD, where increased
age-dependent oxidative damages have been clarified
as a potential key factor leading to a more rapid disease
p ro g re s s i o n ( M e l o v, 2 0 0 4 ; M a n c za k e t a l . , 2 0 0 5 ) .
Mechanistically, Aβ enters mitochondria and generates free
radicals, leading to oxidative damages in postmortem AD brain
cells and, in turn, disrupts mitochondrial function (McLellan
et al., 2003; Crouch et al., 2005). Therefore, mitochondrial
dysfunction is tightly involved in the onset and progression
of AD, which might be an alternative therapeutic target (Yang
et al., 2020). The significant negative correlations between
disease progression and 8-oxo-dG concentration in the
putamen, as well as MPO levels in the caudate of patients with
AD, lends evidence for this hypothesis.
8-oxo-dG, the guanine oxidation product of DNA, can cause
GC to AT transversions. The increased DNA damage and
decreased DNA repair found in AD patients have been closely
correlated to the deficiency in the nonhomologous end joining
repair pathway (De Zio et al., 2012). Studies conducted up to
now are consistent with the assumption that oxidative stress
initiated early in AD brains may contribute to AD progression.
Survival analyses of AD cases point towards an inherently
higher risk of mortality in AD patients with a higher 8-oxo-dG
concentration in the putamen.
The MPO protein, released from azurophilic granules, can
generate cytotoxic reactive oxygen species (ROS) and can
also form neutrophil extracellular traps when combined with
other neutrophil proteins (Aratani, 2018). Clinical studies have
revealed that alterations in the neutrophil activity and levels
of ROS and neutrophil extracellular traps are associated with
AD disease progression (Vitte et al., 2004; Dong et al., 2018).
Pathologically, MPO has been found in the frontal cortex and
hippocampus of AD brains, co-localized with amyloid plaques
and neurofibrillary tangles (NFTs). Moreover, higher MPO
concentration in the blood might be relevant to elevated
levels of oxidative stress markers in AD patient blood samples
(Gellhaar et al., 2017; Swardfager et al., 2017). The MantelCox curve of patient’s survivals showed that AD patients with
a lower MPO level in the caudate had a survival advantage
over those with a higher level.
ROS reacts with cellular components and leads to disruption
of redox homeostasis and cell death. ROS also accelerates
the disease progression and ultimately influences life span.
Moreover, survival time was linked with age of diagnosis, living
status, medication treatment, and epilepsy history.
The correlation of age of onset and disease progression
Depending on the age of onset, PD patients have been
classified into four phenotypes in a new investigation:
younger than 50, 50–59, 60–69, and older than or equal
to 70 years (Pagano et al., 2016). The older the patients
were, the more severe their clinical presentations, including
motor dysfunction and cognitive impairment. This might be
explained by their more significant dopaminergic deficiency
and increased reduction of α-syn and total tau proteins in
their cerebrospinal fluid, indicating that onset age closely
affects the rate of disease progression. On the contrary, earlyonset AD – defined by a young age of onset (< 65 years) –
presents with worse neurodegeneration and a more rapid
disease progression, probably due to chronic microglial overactivation and abnormal glucose hypometabolism (Tondo
et al., 2020). Intriguingly, in this study, we found significant
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negative correlations between age of onset and disease
progression in PD, PDD, DLB, and AD. These trends seem to
indicate that the younger age of onset, the longer survival
time patients experience. However, the common mechanism
and therapy target for slowing disease progression needs to
be explored.
The coupling found in our analysis between the patients’
biochemical parameters and disease progression and survival
is interesting, although limited by the subject numbers and the
brain regions studied. Thus, the more systematic, extensive,
and cross-sectional investigations in a larger population of
patients with different brain regions would further validate
bonafide biomarkers and facilitate understanding of the
mechanisms involved in disease progression. Postmortem
studies using the end-stage cases may not reflect the
biomarker changes of the clinical phases. Therefore, our
results need to be further confirmed by additional clinical
trials and compared with antemortem cerebrospinal fluid and
plasma oxidative damage measures.
Conclusions
Using 8 biochemical parameters examined from the caudate
and putamen of patients with neurodegenerative diseases,
we have performed Spearman and Mantel-Cox analyses
to explore the correlations between these biochemical
parameters, disease progression, and survival. These results
supported the concept that the two characteristic features of
neurodegenerative diseases, disruption of redox homeostasis
and neuroinflammation, can potentiate each other and lead
to the loss and dysfunction of neurons that affect disease
progression. Furthermore, we found that older age of onset
was associated with a faster disease progression in the
neurodegenerative cohorts studied. The apparent lack of
large cohort recruitments hardly supported some degree of
generalizability of our findings. Essential future directions
for research could include studies examining factors that
may influence the progression and survival rates reported in
the present study with larger cohorts of late-onset diseases
and early-onset diseases induced by genetic mutations.
Although the exact detailed mechanisms remain clarified,
our observations might help understand these diseases’
progression and survival rates.
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Additional Figure 1 Correlations between PD stage and disease progression in the patients with Lewy body
diseases.
*P < 0.05. rs: the Spearman's rank correlation coefficient. PD: Parkinson disease.

